Document Detail


New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.
MedLine Citation:
PMID:  23135865     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted mainly through the hormonal and neuronal actions of one of the incretins, GLP-1, which is secreted from L cells localized in the small intestine. The benefits of this therapy over conventional sulfonylureas or insulin injections, such as fewer hypoglycemic events and reduced body weight gain, derive from the glucose-dependent insulinotropic effect. The protective effects of this therapy on vulnerable pancreatic β-cells and against micro/macroangiopathy in T2DM are also most welcome. Indications and/or contraindications for incretin-based therapy should be clarified by prospectively studying the experiences of Japanese T2DM patients undergoing this therapy in the clinical setting.
Authors:
Mitsuyoshi Namba; Tomoyuki Katsuno; Yoshiki Kusunoki; Toshihiro Matsuo; Masayuki Miuchi; Jun-Ichiro Miyagawa
Related Documents :
24971915 - Management and treatment goals in polish patients with type 2 diabetes of more than ten...
11035555 - Recruitment methods for community-based screening for diabetic retinopathy.
24162715 - Recommendations for self-monitoring in pediatric diabetes: a consensus statement by the...
23565385 - Bariatric surgery and diabetes.
8266385 - Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and ins...
23398285 - The impact of predisposing factors on long-term outcome after stroke in diabetic patien...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  -     ISSN:  1437-7799     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan, namba-m@hyo-med.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  KIM-1 expression predicts renal outcomes in IgA nephropathy.
Next Document:  Clinical features and long-term renal outcomes of Japanese patients with obesity-related glomerulopa...